Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01058707 · ClinicalTrials.gov registry record · Phase 1

Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies

A Phase 1 study of Advanced Solid Malignancies, sponsored by Millennium Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
198
Enrollment target
16
Study locations

NCT01058707 is a Phase 1 study of Advanced Solid Malignancies that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 198 participants, roughly in line with the 212-participant average among 6 other Advanced Solid Malignancies trials with a reported enrollment target. The trial reports 16 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01058707, a Phase 1 study of Advanced Solid Malignancies, has completed, sponsored by Millennium Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
198 participants
Enrollment target
16
Study locations

Study Summary

This is a Phase I, open label, Dose Escalation study of oral administration of single agent MLN0128 in participants with Advanced Malignancies followed by an Expansion Phase in participants with renal cell carcinoma, endometrial cancer or urothelial cancer who have measurable disease.

Conditions Studied

Advanced Solid Malignancies

Interventions

  • DRUG MLN0128

Study Locations (16)

Florida

  • - Miami
  • - Sarasota

Michigan

  • - Ann Arbor
  • - Detroit

New York

  • - Buffalo
  • - New York

Other

  • - Barcelona
  • - Valencia

Arizona

  • - Scottsdale

California

  • - Los Angeles

Indiana

  • - Indianapolis

Massachusetts

  • - Boston

Trial Details

FieldValue
Enrollment Target 198 participants
Start Date 2010-01-04
Est. Completion 2019-02-07
Phase Phase 1

Sponsor

Millennium Pharmaceuticals

135 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01058707

The ClinicalTrials.gov registry entry for NCT01058707 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 212-participant average among 6 other Advanced Solid Malignancies trials with a reported enrollment target. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Malignancies appearing as the primary indexed condition, and to 1 intervention - of which MLN0128 is the first listed.

NCT01058707 reports 16 study locations spanning 12 distinct geographic areas - top geographies include Florida, Michigan, New York.

Frequently Asked Questions

What is clinical trial NCT01058707 about?

NCT01058707 is a clinical study titled "Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies". This is a Phase I, open label, Dose Escalation study of oral administration of single agent MLN0128 in participants with Advanced Malignancies followed by an Expansion Phase in participants with renal cell carcinoma, endometrial cancer or urothelial cancer who have measurable disease.

What is the current status of trial NCT01058707?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 198 participants. The study started on 2010-01-04. Estimated completion is 2019-02-07.

What conditions does trial NCT01058707 study?

This clinical trial studies the following conditions: Advanced Solid Malignancies.

What interventions are being tested in trial NCT01058707?

The interventions under investigation include: MLN0128 (DRUG).

Who is sponsoring clinical trial NCT01058707?

This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01058707 being conducted?

This trial has 16 study locations across Arizona, California, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Malignancies

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Malignancies

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.